Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are widely used for the treatment of type 2 diabetes, heart failure and chronic kidney disease due to their proven cardiovascular and renal benefits. The gene discussed is SLC5A2; the disease is chronic kidney disease.